Vanguard Capital Management
AZN icon

Vanguard Capital Management’s AstraZeneca AZN Stock Holding History

Vanguard Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.47B Buy
45,386,190
+346,048
+0.8% +$65.1M 0.18% 86
2026
Q1 		$8.81B Buy
+45,040,142
New +$8.68B 0.22% 77

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management's AZN Position: Q2 2026 in Review

Vanguard Capital Management increased its AstraZeneca (AZN) stake by 0.77% in Q2 2026, buying an estimated $65.1M and bringing the position to 45,386,190 shares worth $8.47B. The position accounts for 0.18% of the portfolio, ranked #86.

Vanguard Capital Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.81B in Q1 2026. 1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Vanguard Capital Management held 45,386,190 shares of AstraZeneca worth $8.47B as of Q2 2026.
  • Vanguard Capital Management bought 346,048 AstraZeneca shares in Q2 2026, an estimated $65.1M.
  • AstraZeneca made up 0.18% of Vanguard Capital Management's portfolio in Q2 2026, its #86 holding.
  • Vanguard Capital Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's AstraZeneca position peaked at $8.81B in Q1 2026.
  • 1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.